Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CIRO: COVID-19 infection risk ontology.
Egami S, Yamamoto Y, Ohmukai I, Okumura T. Egami S, et al. PLoS One. 2023 Mar 30;18(3):e0282291. doi: 10.1371/journal.pone.0282291. eCollection 2023. PLoS One. 2023. PMID: 36996094 Free PMC article.
Funding map using paragraph embedding based on semantic diversity.
Kawamura T, Watanabe K, Matsumoto N, Egami S, Jibu M. Kawamura T, et al. Among authors: egami s. Scientometrics. 2018;116(2):941-958. doi: 10.1007/s11192-018-2783-x. Epub 2018 May 28. Scientometrics. 2018. PMID: 30147200 Free PMC article.
Correction: Catalytic antibodies in arrhythmogenic cardiomyopathy patients cleave desmoglein 2 and N-cadherin and impair cardiomyocyte cohesion.
Yeruva S, Stangner K, Jungwirth A, Hiermaier M, Shoykhet M, Kugelmann D, Hertl M, Egami S, Ishii N, Koga H, Hashimoto T, Weis M, Beckmann BM, Biller R, Schüttler D, Kääb S, Waschke J. Yeruva S, et al. Among authors: egami s. Cell Mol Life Sci. 2023 Sep 20;80(10):296. doi: 10.1007/s00018-023-04942-1. Cell Mol Life Sci. 2023. PMID: 37728633 Free PMC article. No abstract available.
Catalytic antibodies in arrhythmogenic cardiomyopathy patients cleave desmoglein 2 and N-cadherin and impair cardiomyocyte cohesion.
Yeruva S, Stangner K, Jungwirth A, Hiermaier M, Shoykhet M, Kugelmann D, Hertl M, Egami S, Ishii N, Koga H, Hashimoto T, Weis M, Beckmann BM, Biller R, Schüttler D, Kääb S, Waschke J. Yeruva S, et al. Among authors: egami s. Cell Mol Life Sci. 2023 Jul 14;80(8):203. doi: 10.1007/s00018-023-04853-1. Cell Mol Life Sci. 2023. PMID: 37450050 Free PMC article.
IgM to IgG Class Switching Is a Necessary Step for Pemphigus Phenotype Induction in Desmoglein 3-Specific B Cell Receptor Knock-in Mouse.
Nomura H, Wada N, Takahashi H, Kase Y, Yamagami J, Egami S, Iriki H, Mukai M, Kamata A, Ito H, Fujii H, Ishikura T, Koseki H, Watanabe T, Yamada T, Ohara O, Koyasu S, Amagai M. Nomura H, et al. Among authors: egami s. J Immunol. 2022 Feb 1;208(3):582-593. doi: 10.4049/jimmunol.2100781. Epub 2022 Jan 7. J Immunol. 2022. PMID: 34996836
Prognostic Value of Baseline Medications Plus Neutrophil-to-Lymphocyte Ratio in the Effectiveness of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer: A Retrospective Study.
Ogiwara T, Kawazoe H, Egami S, Hashimoto H, Saito Y, Sakiyama N, Ohe Y, Yamaguchi M, Furukawa T, Hara A, Hiraga Y, Jibiki A, Yokoyama Y, Suzuki S, Nakamura T. Ogiwara T, et al. Among authors: egami s. Front Oncol. 2021 Nov 8;11:770268. doi: 10.3389/fonc.2021.770268. eCollection 2021. Front Oncol. 2021. PMID: 34820333 Free PMC article.
82 results